Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1999 Nov-Dec;171(5-6):328–332.

Pharmacogenomics

Wolfgang Sadée 1
PMCID: PMC1308751  PMID: 18751198

Full text

PDF
328

Images in this article

330p330-a
on p.330

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baselga J., Norton L., Albanell J., Kim Y. M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998 Jul 1;58(13):2825–2831. [PubMed] [Google Scholar]
  2. Broly F., Gaedigk A., Heim M., Eichelbaum M., Morike K., Meyer U. A. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 1991 Oct;10(8):545–558. doi: 10.1089/dna.1991.10.545. [DOI] [PubMed] [Google Scholar]
  3. EVANS D. A., MANLEY K. A., McKUSICK V. A. Genetic control of isoniazid metabolism in man. Br Med J. 1960 Aug 13;2(5197):485–491. doi: 10.1136/bmj.2.5197.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Goldenberg M. M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999 Feb;21(2):309–318. doi: 10.1016/S0149-2918(00)88288-0. [DOI] [PubMed] [Google Scholar]
  5. Guengerich F. P. The Environmental Genome Project: functional analysis of polymorphisms. Environ Health Perspect. 1998 Jul;106(7):365–368. doi: 10.1289/ehp.98106365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Iyer V. R., Eisen M. B., Ross D. T., Schuler G., Moore T., Lee J. C., Trent J. M., Staudt L. M., Hudson J., Jr, Boguski M. S. The transcriptional program in the response of human fibroblasts to serum. Science. 1999 Jan 1;283(5398):83–87. doi: 10.1126/science.283.5398.83. [DOI] [PubMed] [Google Scholar]
  7. Kleyn P. W., Vesell E. S. Genetic variation as a guide to drug development. Science. 1998 Sep 18;281(5384):1820–1821. doi: 10.1126/science.281.5384.1820. [DOI] [PubMed] [Google Scholar]
  8. Sadée W. Genomics and drugs: finding the optimal drug for the right patient. Pharm Res. 1998 Jul;15(7):959–963. doi: 10.1023/a:1011949221202. [DOI] [PubMed] [Google Scholar]
  9. Schmid B., Bircher J., Preisig R., Küpfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther. 1985 Dec;38(6):618–624. doi: 10.1038/clpt.1985.235. [DOI] [PubMed] [Google Scholar]
  10. Service R. F. Microchip arrays put DNA on the spot. Science. 1998 Oct 16;282(5388):396–399. doi: 10.1126/science.282.5388.396. [DOI] [PubMed] [Google Scholar]
  11. Tai H. L., Krynetski E. Y., Yates C. R., Loennechen T., Fessing M. Y., Krynetskaia N. F., Evans W. E. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996 Apr;58(4):694–702. [PMC free article] [PubMed] [Google Scholar]
  12. Weinshilboum R. M., Sladek S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980 Sep;32(5):651–662. [PMC free article] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES